Related Videos
Ananda Developments | Cannabis Medicines Targeting Chronic Conditions #ana
➡️ Innovative Cannabis-Based Medicines: Ananda is developing treatments for chronic inflammatory conditions, including drug-resistant epilepsy, chemotherapy-induced nerve pain, and endometriosis, with groundbreaking approaches using cannabis-based compounds. ➡️ Key Partnerships: Collaborating with University College London and Great Ormond Street Hospital, their Phase 3 trials are set to begin patient dosing in mid-2025, targeting significant unmet medical needs. ➡️ Market Opportunity: With the anti-inflammatory drug market projected at $18 billion by 2027, Ananda is poised to address life-altering conditions affecting millions globally.
Stay Updated with StockBox
Receive our weekly newsletter featuring key market moves, company updates, and fresh analysis.
We respect your privacy. Unsubscribe at any time.